Series A/B Medtech Marketing Agency
Demand generation, clinical KOL programs, and channel-building for funded medical device companies scaling from early commercial launch toward full market penetration. Nashville-based, 18 years in device marketing.
Series A and B medtech companies face a marketing challenge that is fundamentally different from what they solved at seed stage: moving from early clinical adoption to systematic commercial scale. The clinical proof exists. The first adopters are in. The question now is how to turn 10 reference sites into 100, convert KOL credibility into a self-reinforcing peer influence network, and build the demand generation infrastructure that reduces dependence on founder-led selling as the commercial team grows.
Updated June 2026
- At Series A, the highest-ROI marketing investment is sales enablement, not brand awareness. Your limited sales force needs battle cards, clinical evidence summaries, and reference site access that close deals faster.
- Series B marketing is about scaling what worked at Series A, converting your early KOL and reference site network into a systematic peer influence engine that drives adoption in new accounts and geographies.
- Digital demand generation becomes essential at Series B to reduce dependence on outbound cold calling as the commercial team grows from 5 reps to 20 to 50 reps.
- Marketing budgets at this stage typically range from an estimated $500,000 to $3,000,000 annually for companies outside the largest device categories. The right allocation weights toward demand generation and clinical evidence, not brand awareness.
What Marketing Stage Are You In as a Series A/B Medtech Company?
Series A and Series B medtech companies are not in the same marketing stage, even though they face some of the same challenges. Understanding which stage you are actually in determines which marketing investments will generate the highest return on the capital you have available.
Series A medtech marketing stage: You have cleared the device (or are within 6 months of clearance). You have 1 to 3 clinical evaluation sites and possibly your first commercial sales. Your primary marketing challenge is generating the clinical credibility and early reference site network that enables your 3 to 8 person sales team to have credible conversations with accounts 2 through 50. The marketing investments with the highest leverage at this stage are clinical evidence acceleration, reference site development, and sales enablement infrastructure.
Series B medtech marketing stage: You have 10 to 50 commercial accounts, a published clinical track record, and an installed base that is generating word-of-mouth in the clinical community. Your commercial team has grown to 10 to 30 sales representatives. Your primary marketing challenge is systematic scale: turning your early KOL network into a self-reinforcing peer influence engine, building digital demand generation that reduces outbound cold calling load on your growing sales team, and expanding geographically into new markets. The marketing investments with the highest leverage at this stage are KOL network expansion, digital demand generation infrastructure, competitive positioning, and geographic expansion support.
What Are the Four Marketing Priorities for Series A/B Medtech Companies?
Sales Enablement Infrastructure
Regulatory-compliant battle cards, clinical evidence summaries, competitive comparison guides, objection-handling documentation, and reference site directories. The materials your sales reps need to convert conversations into commitments faster. At Series A, this is the highest-leverage marketing investment available.
Clinical Evidence Acceleration
Getting your early clinical data into peer-reviewed publication and high-visibility conference presentation as fast as possible. The publication and conference strategy that turns your first clinical outcomes into the evidence base your sales team references in every account conversation.
KOL Network Scaling
Converting your initial 4 to 6 KOL advisors into a 20 to 40 person peer influence network spanning multiple geographic markets. Structured speaker programs, case report publication support, proctorship coordination, and systematic reference site development.
Digital Demand Generation
Building the inbound lead pipeline that reduces dependence on cold outbound as the commercial team scales. Targeted digital campaigns to your clinical buyer, SEO for clinical search terms in your indication, and content marketing that builds organic visibility and credibility.
What Does a Series A/B Medtech Marketing Engagement Look Like?
Medtech companies at the Series A and B stages typically have one of three marketing resource situations when they come to us. Understanding which one fits your situation helps identify the right engagement model:
- No in-house marketing yet. Common at early Series A. The founding team is handling all marketing, often with a single marketing generalist or coordinator. We act as the full marketing department, handling strategy, content, digital, conference coordination, and sales enablement, with a named team that functions as an extension of your internal team.
- One or two in-house marketers. Common at late Series A and early Series B. The in-house team handles day-to-day execution and channel management. We bring category expertise, specialized capabilities (SEO, content, clinical evidence packaging, KOL management), and strategic guidance that the internal team does not have the bandwidth or specialized experience to develop internally.
- A growing in-house marketing team. Common at Series B. Multiple internal marketers are managing specific functions. We handle specialized or overflow work: specific campaign execution, content production at volume, conference strategy, or the KOL relationship management that requires clinical expertise and relationship history in the specialty.
In all three situations, we work on a retainer model with a defined scope, named account team, and clear measurement framework. We do not operate on a project-by-project basis at this stage because the relationship and institutional knowledge that builds up over a sustained engagement is itself a significant asset for the company.
What Services Do We Provide for Series A/B Medtech Companies?
Sales Enablement Library
Battle cards, clinical evidence summaries, competitive comparison guides, objection-handling documentation, and account-specific reference site packages. Built regulatory-compliant with your MLR review process from the start. See our medical device marketing services for full scope.
Clinical Evidence Marketing
Publication strategy, conference abstract planning, evidence summary development, and clinical data packaging that translates your study results into practitioner-relevant marketing assets. We help you build the peer-reviewed evidence base that turns skeptical clinicians into adopters.
KOL Program Management
Speaker program design and management, advisory board structuring, proctorship coordination, and systematic reference site development. Scaling from 6 early advisors to a 30 to 50 person peer influence network across target geographies and academic centers.
Digital Demand Generation
Targeted digital campaigns to clinical buyers in your specialty, SEO for clinical indication and procedure terms, email marketing to prospect lists, and inbound content strategy. Building the pipeline that reduces cold-calling load on your growing sales team. See our healthcare SEO services.
Conference Strategy
Full conference marketing programs for your priority specialty meetings: pre-conference digital campaigns, booth and activation design, satellite symposia planning, KOL dinner events, late-breaking data presentation strategy, and post-conference follow-up campaigns. See our conference marketing services.
Competitive Positioning
Competitive landscape analysis, positioning strategy against established players, and battle card development for every major competitive alternative. Positioning that highlights your clinical and economic differentiators without crossing regulatory lines. Updated as the competitive landscape evolves.
Series A or B and need to scale your commercial engine? Talk to a specialist →
Frequently Asked Questions
What marketing priorities should a Series A medtech company focus on?
The four highest-priority marketing investments at Series A are: clinical evidence acceleration (getting early data into peer-reviewed publication and conference presentation), reference site development (converting your first 5 to 10 adopters into documented clinical references), sales enablement (giving your growing field team the battle cards, case studies, and competitive materials they need to close faster), and digital demand generation (building the inbound pipeline that reduces dependence on outbound cold calling). Among these, sales enablement consistently delivers the highest near-term ROI for Series A companies with a limited sales force.
How much should a Series A medtech company spend on marketing?
Series A medtech companies typically allocate an estimated 15 to 25 percent of total revenue or operational budget to combined marketing and sales. Within the marketing budget, the allocation at this stage weights toward demand generation and sales enablement (estimated 40 to 50 percent of marketing spend), clinical evidence and KOL programs (estimated 25 to 30 percent), conference strategy (estimated 15 to 20 percent), and brand and digital infrastructure (estimated 10 to 15 percent). These are estimates for planning purposes. The right allocation depends on your commercialization model, market dynamics, and runway.
How does a Series B medtech company's marketing differ from Series A?
By Series B, the marketing challenge shifts from market creation to market scaling. You have validated early adopters and need to move from a 10 to 30 site installed base toward 100 to 300 sites. Marketing priorities shift toward systematic KOL and reference site network expansion, digital demand generation at volume, geographic expansion support, and competitive positioning as established players respond to your market presence. Marketing budgets at Series B typically range from an estimated $800,000 to $3,000,000 annually depending on your commercial goals and market size.
What is the biggest marketing mistake Series A/B medtech companies make?
The most common and most costly mistake is underinvesting in sales enablement while overinvesting in brand awareness. At this stage, your limited sales force has a finite number of conversations per week. If reps do not have compelling, regulatory-compliant battle cards, clinical evidence summaries, and reference site access, they will lose deals that better-enabled competitors win. Brand awareness marketing may feel more visible to your board, but the ROI on a well-built sales enablement library consistently exceeds the ROI on general brand campaigns for companies at the Series A and B stages.
Ready to Scale Your Medtech Commercial Engine?
Let's build the demand generation, sales enablement, and KOL programs that take your device from 10 early adopters to 100 commercial accounts.
Talk to a SpecialistFree resource
Series A/B Medtech Marketing Playbook
Sales enablement frameworks, KOL network scaling model, and demand generation blueprint for medtech companies moving from 10 early adopters to 100 commercial accounts.
Free Medtech Marketing Review
What we cover in 30 minutes
- How your device category appears in AI-powered search, including ChatGPT, Perplexity, and Google AI Overviews, and where competitors are cited instead of you
- An honest read on your positioning across the clinical buyer journey: surgeon preference, hospital procurement, IDN formulary or committee evaluation
- Specific observations on your current strategy based on your device class and commercial stage, not a generic agency overview
30 minutes to review how your device is positioned across search, AI tools, and the channels your surgical buyers actually use. Come with your current challenges. Leave with a clear read on where the gaps are.
No prep needed. Bring your website URL and your biggest current challenge.
Quick question
What is your biggest medtech marketing challenge right now?
Tell us in one sentence. We will reply with 2-3 specific ideas for your situation, no pitch.